FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147257535> ?p ?o ?g. }

• W3147257535 abstract "Introduction: This study evaluated the cost-effectiveness of atezolizumab + chemotherapy vs. chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC) in the United States (US). Methods: The three health states partitioned survival (PS) model was used over the lifetime. Effectiveness and safety data were derived from the IMpower133 trial. The parametric survival model and mixture cure model were used for the atezolizumab + chemotherapy group to explore the long-term uncertainty of the effect of immunotherapy, and the parametric survival model was used for the chemotherapy group. Costs were derived from the pricing files of Medicare and Medicaid Services, and utility values were derived from previous studies. Sensitivity analyses were performed to observe model stability. Results: If the mixture cure model was considered for the intervention group, compared with chemotherapy alone, atezolizumab + chemotherapy yielded an additional 0.11 quality-adjusted life-years (QALYs), with an incremental cost of US$84,257. The incremental cost-utility ratio (ICUR) was US$785,848/QALY. If the parametric survival model was considered for the intervention group, atezolizumab + chemotherapy yielded an additional 0.10 QALYs, with an incremental cost of US$84,257; the ICUR was US$827,610/QALY. In the one-way sensitivity analysis, progression-free (PF) and postprogression (PP) utilities were the main drivers. In the scenario analysis (PF utility = 0.673, PP utility = 0.473), the results showed that the ICUR was US$910,557/QALY and US$965,607/QALY when the mixture cure model and parametric survival model was considered for the intervention group, respectively. In the PSA, the probabilities that atezolizumab + chemotherapy would not be cost-effective were 100% if the willingness-to-pay threshold was US$100,000/QALY. Conclusions: The findings of the present analysis suggest that atezolizumab + chemotherapy is not cost-effective in patients receiving first-line treatment for extensive-stage SCLC in the US." @default.
• W3147257535 created "2021-04-13" @default.
• W3147257535 creator A5010267827 @default.
• W3147257535 creator A5025732656 @default.
• W3147257535 creator A5027448697 @default.
• W3147257535 creator A5040533308 @default.
• W3147257535 creator A5045963906 @default.
• W3147257535 creator A5071656221 @default.
• W3147257535 creator A5076952654 @default.
• W3147257535 date "2021-04-06" @default.
• W3147257535 modified "2023-10-05" @default.
• W3147257535 title "Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US" @default.
• W3147257535 cites W2013654057 @default.
• W3147257535 cites W2015548728 @default.
• W3147257535 cites W2017628547 @default.
• W3147257535 cites W2019041562 @default.
• W3147257535 cites W2054348019 @default.
• W3147257535 cites W2056504493 @default.
• W3147257535 cites W2058056848 @default.
• W3147257535 cites W2077019700 @default.
• W3147257535 cites W2114699219 @default.
• W3147257535 cites W2124427232 @default.
• W3147257535 cites W2126499930 @default.
• W3147257535 cites W2130320283 @default.
• W3147257535 cites W2131664752 @default.
• W3147257535 cites W2164665019 @default.
• W3147257535 cites W2171885026 @default.
• W3147257535 cites W2296800272 @default.
• W3147257535 cites W2412666396 @default.
• W3147257535 cites W2508069933 @default.
• W3147257535 cites W2798010797 @default.
• W3147257535 cites W2893050608 @default.
• W3147257535 cites W2893960509 @default.
• W3147257535 cites W2898573540 @default.
• W3147257535 cites W2905118658 @default.
• W3147257535 cites W2911685734 @default.
• W3147257535 cites W2914884420 @default.
• W3147257535 cites W2919228285 @default.
• W3147257535 cites W2945125147 @default.
• W3147257535 cites W2959432976 @default.
• W3147257535 cites W2976462751 @default.
• W3147257535 cites W2979955093 @default.
• W3147257535 cites W2989903818 @default.
• W3147257535 cites W3033359989 @default.
• W3147257535 cites W3118711697 @default.
• W3147257535 doi "https://doi.org/10.3389/fpubh.2021.650392" @default.
• W3147257535 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8055835" @default.
• W3147257535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33889559" @default.
• W3147257535 hasPublicationYear "2021" @default.
• W3147257535 type Work @default.
• W3147257535 sameAs 3147257535 @default.
• W3147257535 citedByCount "3" @default.
• W3147257535 countsByYear W31472575352022 @default.
• W3147257535 countsByYear W31472575352023 @default.
• W3147257535 crossrefType "journal-article" @default.
• W3147257535 hasAuthorship W3147257535A5010267827 @default.
• W3147257535 hasAuthorship W3147257535A5025732656 @default.
• W3147257535 hasAuthorship W3147257535A5027448697 @default.
• W3147257535 hasAuthorship W3147257535A5040533308 @default.
• W3147257535 hasAuthorship W3147257535A5045963906 @default.
• W3147257535 hasAuthorship W3147257535A5071656221 @default.
• W3147257535 hasAuthorship W3147257535A5076952654 @default.
• W3147257535 hasBestOaLocation W31472575351 @default.
• W3147257535 hasConcept C10515644 @default.
• W3147257535 hasConcept C112930515 @default.
• W3147257535 hasConcept C121608353 @default.
• W3147257535 hasConcept C126322002 @default.
• W3147257535 hasConcept C143998085 @default.
• W3147257535 hasConcept C2775949291 @default.
• W3147257535 hasConcept C2776256026 @default.
• W3147257535 hasConcept C2776694085 @default.
• W3147257535 hasConcept C2777701055 @default.
• W3147257535 hasConcept C2780057760 @default.
• W3147257535 hasConcept C3019080777 @default.
• W3147257535 hasConcept C515549039 @default.
• W3147257535 hasConcept C71924100 @default.
• W3147257535 hasConceptScore W3147257535C10515644 @default.
• W3147257535 hasConceptScore W3147257535C112930515 @default.
• W3147257535 hasConceptScore W3147257535C121608353 @default.
• W3147257535 hasConceptScore W3147257535C126322002 @default.
• W3147257535 hasConceptScore W3147257535C143998085 @default.
• W3147257535 hasConceptScore W3147257535C2775949291 @default.
• W3147257535 hasConceptScore W3147257535C2776256026 @default.
• W3147257535 hasConceptScore W3147257535C2776694085 @default.
• W3147257535 hasConceptScore W3147257535C2777701055 @default.
• W3147257535 hasConceptScore W3147257535C2780057760 @default.
• W3147257535 hasConceptScore W3147257535C3019080777 @default.
• W3147257535 hasConceptScore W3147257535C515549039 @default.
• W3147257535 hasConceptScore W3147257535C71924100 @default.
• W3147257535 hasLocation W31472575351 @default.
• W3147257535 hasLocation W31472575352 @default.
• W3147257535 hasOpenAccess W3147257535 @default.
• W3147257535 hasPrimaryLocation W31472575351 @default.
• W3147257535 hasRelatedWork W1466851340 @default.
• W3147257535 hasRelatedWork W2022229528 @default.
• W3147257535 hasRelatedWork W2055244776 @default.
• W3147257535 hasRelatedWork W2413020017 @default.
• W3147257535 hasRelatedWork W2480785262 @default.
• W3147257535 hasRelatedWork W2948845624 @default.
• W3147257535 hasRelatedWork W4205387561 @default.

• next